Derek Archila
Stock Analyst at Wells Fargo
(4.26)
# 390
Out of 5,090 analysts
202
Total ratings
54.89%
Success rate
13.88%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANNX Annexon | Maintains: Overweight | $14 → $27 | $4.61 | +485.68% | 4 | Nov 19, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $20 → $19 | $11.00 | +72.73% | 1 | Nov 14, 2025 | |
| SEPN Septerna | Upgrades: Overweight | $18 → $28 | $26.76 | +4.63% | 5 | Nov 14, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $76 → $84 | $73.64 | +14.07% | 1 | Nov 11, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $395 → $479 | $458.12 | +4.56% | 1 | Nov 11, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Overweight | $11 → $14 | $8.72 | +60.55% | 5 | Nov 7, 2025 | |
| GLUE Monte Rosa Therapeutics | Maintains: Equal-Weight | $10 → $13 | $17.41 | -25.33% | 6 | Nov 7, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $16 → $15 | $12.79 | +17.28% | 8 | Nov 6, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $123 → $106 | $51.37 | +106.35% | 2 | Nov 5, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $53 → $69 | $66.62 | +3.57% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $44.41 | +82.39% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $31 | $7.80 | +297.44% | 3 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $89 → $97 | $102.52 | -5.38% | 10 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $21 | $18.09 | +16.09% | 6 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $44.36 | -32.37% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $6.25 | -20.00% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $32 | $23.63 | +35.42% | 13 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $2.67 | +274.53% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.82 | +21.37% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $29.45 | +29.03% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $8.66 | +246.42% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.55 | -21.57% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $289 → $295 | $205.44 | +43.59% | 14 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $1.39 | +259.71% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $27 → $26 | $32.02 | -18.80% | 2 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $741 → $756 | $901.17 | -16.11% | 12 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $11.12 | +52.88% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $129 | $104.60 | +23.33% | 6 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $3.32 | +351.81% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $26.69 | -47.55% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $22.84 | +97.02% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $3.73 | +436.19% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.13 | +335.84% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $31.59 | +510.95% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $76.34 | -46.29% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $16.54 | +867.35% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $13.90 | +331.65% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $5.39 | +438.03% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.31 | +3,716.79% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $22.98 | +121.93% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $13.44 | +554.76% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $23.99 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $28.46 | - | 2 | Aug 3, 2017 |
Annexon
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $4.61
Upside: +485.68%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $11.00
Upside: +72.73%
Septerna
Nov 14, 2025
Upgrades: Overweight
Price Target: $18 → $28
Current: $26.76
Upside: +4.63%
BridgeBio Pharma
Nov 11, 2025
Maintains: Overweight
Price Target: $76 → $84
Current: $73.64
Upside: +14.07%
Alnylam Pharmaceuticals
Nov 11, 2025
Maintains: Equal-Weight
Price Target: $395 → $479
Current: $458.12
Upside: +4.56%
Ventyx Biosciences
Nov 7, 2025
Maintains: Overweight
Price Target: $11 → $14
Current: $8.72
Upside: +60.55%
Monte Rosa Therapeutics
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $10 → $13
Current: $17.41
Upside: -25.33%
Arvinas
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $12.79
Upside: +17.28%
Soleno Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $123 → $106
Current: $51.37
Upside: +106.35%
Kymera Therapeutics
Nov 5, 2025
Maintains: Overweight
Price Target: $53 → $69
Current: $66.62
Upside: +3.57%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $44.41
Upside: +82.39%
Oct 30, 2025
Maintains: Overweight
Price Target: $27 → $31
Current: $7.80
Upside: +297.44%
Oct 29, 2025
Maintains: Overweight
Price Target: $89 → $97
Current: $102.52
Upside: -5.38%
Oct 23, 2025
Maintains: Overweight
Price Target: $22 → $21
Current: $18.09
Upside: +16.09%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $44.36
Upside: -32.37%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $6.25
Upside: -20.00%
Oct 15, 2025
Upgrades: Overweight
Price Target: $29 → $32
Current: $23.63
Upside: +35.42%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.67
Upside: +274.53%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.82
Upside: +21.37%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $29.45
Upside: +29.03%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $8.66
Upside: +246.42%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.55
Upside: -21.57%
Aug 8, 2025
Maintains: Overweight
Price Target: $289 → $295
Current: $205.44
Upside: +43.59%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $1.39
Upside: +259.71%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $27 → $26
Current: $32.02
Upside: -18.80%
Jul 31, 2025
Maintains: Overweight
Price Target: $741 → $756
Current: $901.17
Upside: -16.11%
Jul 25, 2025
Initiates: Overweight
Price Target: $17
Current: $11.12
Upside: +52.88%
Jul 10, 2025
Maintains: Overweight
Price Target: $91 → $129
Current: $104.60
Upside: +23.33%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $3.32
Upside: +351.81%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $26.69
Upside: -47.55%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $22.84
Upside: +97.02%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $3.73
Upside: +436.19%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $4.13
Upside: +335.84%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $31.59
Upside: +510.95%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $76.34
Upside: -46.29%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $16.54
Upside: +867.35%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $13.90
Upside: +331.65%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $5.39
Upside: +438.03%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.31
Upside: +3,716.79%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $22.98
Upside: +121.93%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $13.44
Upside: +554.76%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $23.99
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $28.46
Upside: -